Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Giulio Cavalli and Giacomo De Luca.
Giulio Cavalli
Connection Strength
3.892
Giacomo De Luca
  1. Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. Ann Intern Med. 2018 12 04; 169(11):819-820.
    View in: PubMed
    Score: 0.779
  2. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
    View in: PubMed
    Score: 0.232
  3. Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. Rheumatology (Oxford). 2021 01 05; 60(1):465-467.
    View in: PubMed
    Score: 0.231
  4. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol. 2020; 11:598308.
    View in: PubMed
    Score: 0.230
  5. Mavrilimumab for severe COVID-19 - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e662-e663.
    View in: PubMed
    Score: 0.225
  6. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
    View in: PubMed
    Score: 0.222
  7. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
    View in: PubMed
    Score: 0.220
  8. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020 01 01; 59(1):171-175.
    View in: PubMed
    Score: 0.215
  9. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther. 2019 Feb 25; 21(1):69.
    View in: PubMed
    Score: 0.203
  10. Myocarditis: An Interleukin-1-Mediated Disease? Front Immunol. 2018; 9:1335.
    View in: PubMed
    Score: 0.193
  11. Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". Circulation. 2018 05 29; 137(22):2421-2422.
    View in: PubMed
    Score: 0.192
  12. QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. Int J Cardiol. 2017 07 15; 239:33.
    View in: PubMed
    Score: 0.181
  13. Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al. Clin Exp Rheumatol. 2017 Mar-Apr; 35 Suppl 103(1):221.
    View in: PubMed
    Score: 0.177
  14. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J Clin Rheumatol. 2021 Jun 01; 27(4):e143-e146.
    View in: PubMed
    Score: 0.059
  15. The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. J Clin Med. 2021 May 04; 10(9).
    View in: PubMed
    Score: 0.059
  16. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front Immunol. 2021; 12:675678.
    View in: PubMed
    Score: 0.059
  17. Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. Microvasc Res. 2021 01; 133:104071.
    View in: PubMed
    Score: 0.056
  18. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli. Ann Rheum Dis. 2020 Jul 31.
    View in: PubMed
    Score: 0.056
  19. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020 10; 79(10):1277-1285.
    View in: PubMed
    Score: 0.056
  20. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
    View in: PubMed
    Score: 0.055
  21. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018 11; 57:e11-e12.
    View in: PubMed
    Score: 0.049
  22. Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. Front Immunol. 2018; 9:1233.
    View in: PubMed
    Score: 0.048
  23. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. Oncoimmunology. 2018; 7(7):e1440929.
    View in: PubMed
    Score: 0.047
  24. Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. J Neurol. 2018 Feb; 265(2):273-284.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.